BRPI9909191B8 - derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende - Google Patents

derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende

Info

Publication number
BRPI9909191B8
BRPI9909191B8 BRPI9909191A BRPI9909191A BRPI9909191B8 BR PI9909191 B8 BRPI9909191 B8 BR PI9909191B8 BR PI9909191 A BRPI9909191 A BR PI9909191A BR PI9909191 A BRPI9909191 A BR PI9909191A BR PI9909191 B8 BRPI9909191 B8 BR PI9909191B8
Authority
BR
Brazil
Prior art keywords
alkyl
optionally substituted
amino
hydrogen
mono
Prior art date
Application number
BRPI9909191A
Other languages
English (en)
Inventor
De Corte Bart
Yung Ho Chih
William Ludovici Donald
Heeres Jan
Jeanne Alfons Van Aken Koen
Jozef Lodewijk Marcel Andries Koenraad
Maria Henricus Koymans Lucien
Rene De Jonge Marc
August Constant Janssen Marcel
Joseph Kukla Michael
Adriaan Jan Janssen Paul
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98201587A external-priority patent/EP0945442A1/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP1999/002043 external-priority patent/WO1999050250A1/en
Publication of BR9909191A publication Critical patent/BR9909191A/pt
Publication of BRPI9909191B1 publication Critical patent/BRPI9909191B1/pt
Publication of BRPI9909191B8 publication Critical patent/BRPI9909191B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

patente de invenção: <b>"derivados de pirimidina inibidores do hiv"<d>. a presente invenção refere-se ao uso dos compostos de fórmula (i), aos n-óxidos, aos sais de adição farmaceuticamente aceitáveis e às formas estereoquimicamente isoméricas destes, onde a é ch, cr^ 4^ ou n; n é 0 a 4; q é hidrogênio ou -nr¹r²; r¹ e r² são selecionados dentre hidrogênio, hidróxi, c~ 1-12~ alquila, c~ 1-12~ alquilóxi, c~ 1-12~ alquilcarbonila, c~ 1-12~ alquiloxicarbonila, arila, amino, mono- ou di(c~ 1-12~alquil)-amino, mono- ou di(c~ 1-12~alquil)aminocarbonila, onde cada um dos grupos c~ 1-12~ alquila supramencionados, podem opcionalmente, ser substituídos; ou r¹ e r² considerados juntos, podem formar pirrolidinila, piperidinila, morfolinila, azido ou mono- ou di(c~ 1-12~ alquil)amino-c~ 1-4~ alquilideno; r³ é hidrogênio, arila, c~ 1-6~ alquilcarbonila, c~ 1-6~ alquila opcionalmente substituída, c~ 1-6~ alquiloxicarbonila, e r~ 4~ é hidróxi, halo, c~ 1-6~ alquila opcionalmente substituída, c~ 1-6~ alquilóxi, ciano, aminocarbonila, nitro, amino, trihalometila, trihalometilóxi; r^ 5^ é hidrogênio ou c~ 1-4~ alquila; l é c~ 1-10~ alquila, c~ 3-10~ alquenila, c~ 3-10~ alquinila, c~ 3-7~ cicloalquila opcionalmente substituídas, ou l é -x^ 1^-r^ 6^ ou -x^ 2^-alq-r^ 7^; onde r^ 6^ e r^ 7^ são fenila opcionalmente substituída; x¹ e x² são cada qual, -nr³-, -nh-nh-, -n=n-, -o-, -s-, -s(=o)- ou -s(=o)~ 2~-; alq é c~ 1-4~ alcanodiila; arila é fenila opcionalmente substituída; het é um radical heterocíclico aromático ou alifático, opcionalmente substituído; para a produção de um medicamento para o tratamento de indivíduos sofrendo de infecção por hiv (vírus da imunodeficiência humana). a invenção refere-se também a novos compostos que são um subgrupo dos compostos de fórmula (i), à sua preparação e a composições compreendendo os mesmos.
BRPI9909191A 1998-03-27 1999-03-24 derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende BRPI9909191B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7963298P 1998-03-27 1998-03-27
US60/079,632 1998-03-27
EP98201587A EP0945442A1 (en) 1998-03-27 1998-05-14 Trisubstituted pyrimidine derivatives
EP98201587.7 1998-05-14
EP98203948.9 1998-11-25
EP98203948 1998-11-25
PCT/EP1999/002043 WO1999050250A1 (en) 1998-03-27 1999-03-24 Hiv inhibiting pyrimidine derivatives

Publications (3)

Publication Number Publication Date
BR9909191A BR9909191A (pt) 2000-12-05
BRPI9909191B1 BRPI9909191B1 (pt) 2018-04-03
BRPI9909191B8 true BRPI9909191B8 (pt) 2021-07-06

Family

ID=43734825

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9909191A BRPI9909191B8 (pt) 1998-03-27 1999-03-24 derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende

Country Status (6)

Country Link
US (5) US6197779B1 (pt)
KR (1) KR100643419B1 (pt)
AR (1) AR014785A1 (pt)
BR (1) BRPI9909191B8 (pt)
DE (1) DE69943247D1 (pt)
ES (1) ES2361146T3 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID28376A (id) 1998-11-10 2001-05-17 Janssen Pharmaceutica Nv Pirimidina yang menghambat replikasi hiv
TR200200763T2 (tr) * 1999-09-24 2003-09-22 Janssen Pharmaceutica N.V. Antiviral bileşimler
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US8101629B2 (en) * 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JP4460292B2 (ja) * 2001-10-17 2010-05-12 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7288547B2 (en) * 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
AU2003216591A1 (en) * 2002-04-10 2003-10-20 Orichid Chemicals And Pharmaceuticals Limited Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological
IL166241A0 (en) * 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
US7399856B2 (en) * 2002-08-09 2008-07-15 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
EA009478B1 (ru) * 2002-08-23 2008-02-28 Ардеа Байосайенсиз, Инк. Ненуклеозидные ингибиторы обратной транскриптазы
WO2004048343A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
ES2421139T3 (es) * 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
EA200602045A1 (ru) * 2004-05-19 2007-06-29 Басф Акциенгезельшафт 2-замещённые пиримидины
ME01512B (me) 2004-08-25 2014-04-20 Ardea Biosciences Inc S-triazolil alfa-merkaptoacetanilida kao inhibitori HIV reversne transkriptaze
WO2007050087A1 (en) * 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
ATE520672T1 (de) * 2004-09-30 2011-09-15 Tibotec Pharm Ltd Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
JP2008540436A (ja) * 2005-05-03 2008-11-20 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋキナーゼインヒビターおよびそれらの使用
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
WO2007053452A1 (en) * 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
ES2441958T3 (es) * 2006-07-11 2014-02-07 Janssen Pharmaceutica Nv Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina H4
EP2132211A4 (en) 2006-11-09 2011-12-07 Ardea Biosciences Inc 4-CYANPHENYLAMINO-SUBSTITUTED BICYCLIC AND HETEROCYCLIC COMPOUNDS AS AN HIV HEMMER
JP5600063B2 (ja) 2007-10-19 2014-10-01 セルジーン アビロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
US7989465B2 (en) * 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
BRPI0819847B1 (pt) 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US20110319392A1 (en) * 2009-03-12 2011-12-29 George Adjabeng Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors
US8367315B2 (en) * 2010-03-05 2013-02-05 Adan Rios Inactivation of reverse transcriptases by azido-diarylpyrimidines
AU2011260323A1 (en) 2010-06-04 2012-11-15 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as LRRK2 modulators
JP2013537240A (ja) 2010-09-20 2013-09-30 カリウス セラピューティクス エスエー 糖尿病および脂質異常症の処置のための方法および組成物
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
KR101566091B1 (ko) 2010-11-10 2015-11-04 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
US9126949B2 (en) 2011-04-25 2015-09-08 Hetero Research Foundation Process for rilpivirine
EP2755959B1 (en) * 2011-09-16 2018-05-16 Hetero Research Foundation Rilpivirine hydrochloride
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
CN111187222B (zh) * 2020-01-16 2021-09-24 山东大学 一种取代嘧啶类衍生物及其制备方法和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2478030A (en) * 1945-05-24 1949-08-02 Gen Electric Method of making electromagnetic induction apparatus
US2748124A (en) * 1954-05-06 1956-05-29 Searle & Co 1-(4-anilino-2-pyrimidino)-3-alkylureas
GB1010998A (en) 1962-10-09 1965-11-24 British Petroleum Co Pyrimidine derivatives
US3478030A (en) 1966-06-27 1969-11-11 Abbott Lab Benzamide substituted anilino aminopyrimidines
GB1483271A (en) 1975-03-22 1977-08-17 Ciba Geigy Ag Pigment complexes
GB1477349A (en) 1975-09-24 1977-06-22 Ciba Geigy Ag Azo pigments
JPS57203072A (en) * 1981-06-05 1982-12-13 Sankyo Co Ltd 4-anilinopyrimidine derivative, its preparation, antidepressant comprising it as active ingredient
JPS59151386A (ja) 1983-01-31 1984-08-29 Fujitsu Ltd 半導体記憶装置
US4659363A (en) * 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
JPH0784445B2 (ja) 1986-12-03 1995-09-13 クミアイ化学工業株式会社 ピリミジン誘導体および農園芸用殺菌剤
US4980371A (en) * 1988-12-21 1990-12-25 Merrell Dow Pharmaceuticals Antiretroviral furan ketones
IE63502B1 (en) 1989-04-21 1995-05-03 Zeneca Ltd Aminopyrimidine derivatives useful for treating cardiovascular disorders
JPH02300264A (ja) 1989-05-16 1990-12-12 Fuji Photo Film Co Ltd アミノピリミジンアゾメチン色素とその製造方法
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
US5064963A (en) * 1990-04-25 1991-11-12 American Cyanamid Company Process for the synthesis of n-(3-(1h-imidazol-1-yl)phenyl-4-(substituted)-2-pyrimidinamines
GB9012592D0 (en) * 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
JPH04159381A (ja) 1990-10-23 1992-06-02 Arakawa Chem Ind Co Ltd ロジンエステルの製造方法
TW234077B (pt) 1992-07-17 1994-11-11 Shell Internat Res Schappej B V
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
JP3398152B2 (ja) 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US5574040A (en) * 1995-01-06 1996-11-12 Picower Institute For Medical Research Pyrimidine compounds and methods of use to derivatize neighboring lysine residues in proteins under physiologic conditions
JP3691101B2 (ja) 1995-01-24 2005-08-31 三洋電機株式会社 有機エレクトロルミネッセンス素子
JPH09101590A (ja) 1995-07-28 1997-04-15 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料およびその包装体
US5837436A (en) 1995-07-28 1998-11-17 Fuji Photo Film Co., Ltd. Silver halide color photographic material and package thereof
JPH0968784A (ja) 1995-08-31 1997-03-11 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JPH0980676A (ja) 1995-09-13 1997-03-28 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料およびその包装体
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
JP2000111191A (ja) 1998-08-04 2000-04-18 Tokyo Gas Co Ltd 吸収冷温水機
JP4159381B2 (ja) 2003-02-24 2008-10-01 花王株式会社 歯ブラシ

Also Published As

Publication number Publication date
US20010011094A1 (en) 2001-08-02
DE69943247D1 (de) 2011-04-14
KR20010034269A (ko) 2001-04-25
BR9909191A (pt) 2000-12-05
US6440986B2 (en) 2002-08-27
US6903213B2 (en) 2005-06-07
BRPI9909191B1 (pt) 2018-04-03
KR100643419B1 (ko) 2006-11-10
US20030083317A1 (en) 2003-05-01
US8026248B2 (en) 2011-09-27
US20050192305A1 (en) 2005-09-01
US6197779B1 (en) 2001-03-06
US20050197354A1 (en) 2005-09-08
AR014785A1 (es) 2001-03-28
ES2361146T3 (es) 2011-06-14

Similar Documents

Publication Publication Date Title
BR9909191A (pt) Derivados de pirimidina inibidores do hiv
BR9909197A (pt) Derivados 1,3,5-triazina tri-substituìdos para o tratamento de infecções por hiv
EA200000990A1 (ru) Вич-ингибирующие производные пиримидина
BR9704937A (pt) Derivados de diamino-1,3,5-triazina substituìda
BRPI0407732A (pt) pirimidinas e triazinas inibidoras da replicação de hiv
AR023659A1 (es) Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
HUP0100142A2 (hu) Szubsztituált ciklopentán- és ciklopenténszármazékok és alkalmazásuk neuraminidáz-inhibitorokként
AR024227A1 (es) Pirimidinas inhibidoras de replicacion de hiv, un proceso para su preparacion, el uso de las mismas para la manufactura de un medicamento, composiciones farmaceuticas, y un proceso para prepararlas
HUP0203453A2 (en) Quinazoline derivatives as vegf inhibitors, process for their preparation, pharmaceutical compositions containing them and their use
AR018175A1 (es) Compuestos de indol-3-glioxilamidas sustituidas, utiles como medicamentos antitumorales, composiciones farmaceuticas formuladas con dichos derivados,utilizacion de dichos derivados para la preparacion de medicamentos antitumorales y los medicamentos asi preparados.
BR0312560A (pt) Novas espiropiperidinas ou espiropirrolidinas tricìclicas
BR0111263A (pt) Derivados de 2-aminocarbonil-9h-purina
BR9803179A (pt) Antagonistas receptores de ccr-3.
EA200900358A1 (ru) Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
EA200600225A1 (ru) Производные пиперазина для лечения вич инфекций
HUP0202932A2 (hu) Heterociklusos vegyületek és ezeket tartalmazó, kemokin receptor modulátorként alkalmazható gyógyászati készítmények
BR9915735A (pt) Antagonistas receptores de ccr-3 de piperidina
BRPI0417268A (pt) benzimidazóis que contêm morfolinila, como inibidores da replicação de vìrus sinciciais respiratórios
BRPI0111142C1 (pt) utilização de derivados de biguanida ou sais farmaceuticamente aceitáveis dos mesmos para fabricação de medicamento tendo um efeito cicatrizante
BR9910448A (pt) Azóis solúveis em água como antifúngicos de amplo aspectro
BR0100234A (pt) Compostos de piperidina-4-sulfonamida, processo para a sua preparação e composições farmacêuticas contendo os mesmos
BR9814376A (pt) Composto ou um pró-medicamento correspondente, ou um sal farmaceuticamente aceitável ou solvato de um tal composto ou um pró-medicamento deste, uso destes, composição farmacêutica, processo para o tratamento de um paciente humano ou animal não humano sofrendo de, ou sujeito a, condições que podem ser melhoradas pela admnistração de um inibidor da adesão celular mediada por &amp;4ß1, e, resina
GB0223232D0 (en) Chemical compounds
HUP0402033A2 (hu) 2-Amino-4-piridil-metil-tiazolin-származékok alkalmazása az indukálható NO-szintetáz inhibitoraként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE500231T1 (de) Hiv hemmende pyrimidin derivate

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S)8O, 11 E 13 DA LEI NO 9.279/1996 (LPI).

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229-C DA LPI.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/03/99, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO